Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INVONASDAQ:NVCNNASDAQ:TTOONASDAQ:UTRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVOINVO Bioscience$0.88+3.7%$1.63$0.63▼$3.50$3.34M1.431.59 million shs117,277 shsNVCNNeovasc$30.03$29.69$4.59▼$30.07$82.28M1.756,993 shs1 shsTTOOT2 Biosystems$0.14+1.8%$0.15$0.06▼$6.00$2.95M0.48579,543 shs72,967 shsUTRSMinerva Surgical$0.00$0.00▼$0.00$1K3.67259 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVOINVO Bioscience+3.66%-12.45%-45.96%-58.31%+15.18%NVCNNeovasc0.00%0.00%0.00%0.00%0.00%TTOOT2 Biosystems+1.82%-6.60%-12.50%+15.70%-97.23%UTRSMinerva Surgical0.00%0.00%0.00%0.00%-99.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINVOINVO BioscienceN/AN/AN/AN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/AN/AN/AN/ATTOOT2 Biosystems2.4659 of 5 stars3.05.00.00.00.00.00.0UTRSMinerva SurgicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINVOINVO Bioscience 0.00N/AN/AN/ANVCNNeovasc 0.00N/AN/AN/ATTOOT2 Biosystems 2.00Hold$5.003,471.43% UpsideUTRSMinerva Surgical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINVOINVO Bioscience$5.77M0.58N/AN/A($2.06) per share-0.43NVCNNeovasc$3.81M21.60N/AN/A$5.77 per share5.20TTOOT2 Biosystems$7.68M0.38N/AN/A($6.91) per share-0.02UTRSMinerva Surgical$51.69M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINVOINVO Bioscience-$8.03MN/A0.00∞N/A-122.79%N/A-36.94%N/ANVCNNeovasc-$41.20M-$15.08N/A∞N/A-1,082.92%-127.25%-80.31%N/ATTOOT2 Biosystems-$50.08MN/A0.00∞N/A-563.16%N/A-174.06%7/28/2025 (Estimated)UTRSMinerva Surgical-$34.11MN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINVOINVO BioscienceN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/AUTRSMinerva SurgicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINVOINVO BioscienceN/A0.300.27NVCNNeovasc0.802.962.85TTOOT2 BiosystemsN/A0.400.24UTRSMinerva SurgicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINVOINVO Bioscience12.02%NVCNNeovasc1.64%TTOOT2 Biosystems23.18%UTRSMinerva SurgicalN/AInsider OwnershipCompanyInsider OwnershipINVOINVO Bioscience3.50%NVCNNeovascN/ATTOOT2 Biosystems0.03%UTRSMinerva Surgical8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINVOINVO Bioscience253.81 million3.77 millionNo DataNVCNNeovasc492.74 millionN/ANot OptionableTTOOT2 Biosystems18021.04 million21.04 millionOptionableUTRSMinerva Surgical1608.88 million8.12 millionNot OptionableNVCN, UTRS, INVO, and TTOO HeadlinesRecent News About These CompaniesMinerva Surgical Inc.January 10, 2024 | thestreet.comWhy Is Minerva Surgical (UTRS) Stock Down 50% Today?December 18, 2023 | markets.businessinsider.comMinerva Surgical Inc UTRSDecember 17, 2023 | morningstar.comMMinerva Surgical, Inc.: Minerva Surgical Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | finanznachrichten.deMinerva Surgical GAAP EPS of -$0.81 misses by $0.27, revenue of $12M misses by $1.93MNovember 14, 2023 | msn.comMinerva Surgical Reports Third Quarter 2023 Financial ResultsNovember 13, 2023 | finance.yahoo.comAccelmed Files Transaction Statement on Schedule 13E-3 with Securities and Exchange CommissionSeptember 29, 2023 | finance.yahoo.comMinerva Surgical Inc (UTRS) Becoming More Attractive for InvestorsSeptember 27, 2023 | knoxdaily.comKUTRS Shares Experience Surge in ValueAugust 25, 2023 | knoxdaily.comKMinerva Surgical Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comMinerva Surgical, Inc. (UTRS) Reports Q2 Loss, Misses Revenue EstimatesAugust 3, 2023 | finance.yahoo.comInvestors in Minerva Surgical (NASDAQ:UTRS) from a year ago are still down 86%, even after 51% gain this past weekMay 25, 2023 | finance.yahoo.comWhy Minerva Surgical Shares Are Taking Off WednesdayMay 24, 2023 | msn.comPatent Grant Sends Healthcare Shares Soaring PremarketMay 24, 2023 | theglobeandmail.comWhy Is Minerva Surgical (UTRS) Stock Up 229% Today?May 24, 2023 | msn.comQ1 2023 Minerva Surgical Inc Earnings CallMay 3, 2023 | finance.yahoo.comMinerva Surgical Reports First Quarter 2023 Financial ResultsMay 2, 2023 | finance.yahoo.comModified Minerva orthosis proven helpful in pediatric patients following airway surgeryMay 2, 2023 | medicalxpress.comMMinerva Surgical to Announce First Quarter 2023 Financial ResultsApril 18, 2023 | finance.yahoo.comMinerva Surgical, Inc. (NASDAQ:UTRS) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?NVCN, UTRS, INVO, and TTOO Company DescriptionsINVO Bioscience NASDAQ:INVO$0.88 +0.03 (+3.66%) As of 07/2/2025INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.Neovasc NASDAQ:NVCNNeovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.T2 Biosystems NASDAQ:TTOO$0.14 +0.00 (+1.82%) As of 07/3/2025 12:05 PM EasternT2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Minerva Surgical NASDAQ:UTRSMinerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
